Results 261 to 270 of about 1,817,538 (306)
Some of the next articles are maybe not open access.
Nature Reviews Drug Discovery, 2010
Oncology has become one of the major focus areas for pharmaceutical and biotechnology companies. In 2009, ~16,000 of the ~40,000 Phase I, II and III trials listed on ClinicalTrials.gov were related to cancer (~40%). This large interest stems from the existence of high unmet need for improved treatments of multiple types of cancer and the substantial ...
openaire +2 more sources
Oncology has become one of the major focus areas for pharmaceutical and biotechnology companies. In 2009, ~16,000 of the ~40,000 Phase I, II and III trials listed on ClinicalTrials.gov were related to cancer (~40%). This large interest stems from the existence of high unmet need for improved treatments of multiple types of cancer and the substantial ...
openaire +2 more sources
Nature, 2004
Disruption of the normal regulation of cell-cycle progression and division lies at the heart of the events leading to cancer. Complex networks of regulatory factors, the tumour microenvironment and stress signals, such as those resulting from damaged DNA, dictate whether cancer cells proliferate or die.
openaire +2 more sources
Disruption of the normal regulation of cell-cycle progression and division lies at the heart of the events leading to cancer. Complex networks of regulatory factors, the tumour microenvironment and stress signals, such as those resulting from damaged DNA, dictate whether cancer cells proliferate or die.
openaire +2 more sources
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2009
The definition of targets in the metastatic process has been a major step. Targeted therapy is composed of molecules which block these targets including ligand-binding antibody or receptor-inhibitors. Their mechanisms of action are not limited to angiogenesis but also concern apoptosis, bone marrow progenitor stem cells, vascularisation and immune ...
A, Méjean, T, Lebret
openaire +1 more source
The definition of targets in the metastatic process has been a major step. Targeted therapy is composed of molecules which block these targets including ligand-binding antibody or receptor-inhibitors. Their mechanisms of action are not limited to angiogenesis but also concern apoptosis, bone marrow progenitor stem cells, vascularisation and immune ...
A, Méjean, T, Lebret
openaire +1 more source
Nihon rinsho. Japanese journal of clinical medicine, 2014
Rituximab, a genetically engineered chimeric monoclonal antibody that specifically binds to CD20, is the first monoclonal antibody approved for the treatment of B-cell lymphoma. It has been shown that rituximab exerts cytotoxic activities through CDC and ADCC, and that it directly induces apoptosis.
openaire +1 more source
Rituximab, a genetically engineered chimeric monoclonal antibody that specifically binds to CD20, is the first monoclonal antibody approved for the treatment of B-cell lymphoma. It has been shown that rituximab exerts cytotoxic activities through CDC and ADCC, and that it directly induces apoptosis.
openaire +1 more source
Breast Cancer Therapy–Classical Therapy, Drug Targets, and Targeted Therapy
2014Therapeutic options for breast cancer treatment include chemotherapy, endocrine therapy, and novel targeted therapy. In the adjuvant setting, chemotherapy is indicated for early breast cancer treatment based on tumor stage, histological grading, estrogen and progesterone receptor, proliferative index, and human epidermal growth factor receptor.
openaire +1 more source